All Updates

All Updates

icon
Filter
FDA approval
Signet Therapeutics receives IND approval from FDA for gastric cancer treatment
AI Drug Discovery
Jul 1, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
AI Drug Discovery

AI Drug Discovery

Jul 1, 2024

Signet Therapeutics receives IND approval from FDA for gastric cancer treatment

FDA approval

  • AI-based oncology therapy developer Signet Therapeutics has received FDA approval for its IND application for sigx1094, a targeted drug for diffuse gastric cancer (DGC). Following the approval, the company is prepared to commence Phase I clinical trials to assess the treatment's safety and efficacy against DGC and other advanced solid tumors.

  • Sigx1094 was developed using Signet's proprietary organoid disease model platform and AI in collaboration with AI-powered R&D platform company XtalPi. Organoids refer to 3D miniaturized versions of organs or tissues derived from stem cells. They can mimic an organ's key function, structure, and biological complexity, aiding in drug development and clinical trials. 

  • Signet Therapeutics focuses on developing targeted oncology therapeutics, leveraging advanced AI technology and disease models to enhance drug discovery and development processes. The company’s approach uses real-world cancer genomics data to create 3D organoid models, providing more clinically relevant data.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.